00:16다음 영상에서 만나요
00:30The order discount tool lifted reorder conversion 43% above its control group in the Seoul Pilot
00:35The $97.8 billion global obesity drug market is actively looking for non-GLP1 challengers Korean Pharma is already licensing
00:45It's Tuesday, August 25th
00:48Let's look at what this means for startups and entrepreneurs in Korea
00:52Mirai Asset Group launched DigitalX, the rebranded Corbett Exchange, with zero trading fees across all KRW markets for 12 months
01:02Backed by a $50.1 billion, approximately $35.7 million equity injection raising the parent stake to 97.15%
01:12The Group's $784.1 trillion, approximately $560 billion, customer asset base represents a distribution network that incumbents Upbit and BitHum,
01:24controlling roughly 98% of Korean crypto volume, cannot replicate overnight
01:30Simultaneously, Korea's data center regulations are crystallizing into operational risk
01:35Gwacheon proposes 200-300 meter residential buffers for facilities above 5 megawatts
01:41Seoul's 25-district heads-backed mandatory architectural review
01:45And no national standard exists
01:49Here's what the numbers show
01:50DigitalX holds approximately 0.5% of Korea's crypto market versus the 98% incumbent duopoly
01:57But Mirai Asset's equity raise and one-year zero-fee strategy signals a long-duration acquisition play, not a break
02:05-even model
02:06Matter of fact, Bayman's reorder discount raised reorder conversion to 10% versus 7% for non-participating stores
02:14And shortened average reorder time from 8.3 to 6.4 days
02:19Direct lifetime value improvement for food service operators on the platform
02:23Korea's data center fragmentation creates asymmetric risk
02:28Edge data centers under 10 megawatts serve AI inference and fintech workloads
02:33But Gwacheon's 5-megawatt threshold subjects even small urban facilities to 200-300-meter residential setbacks
02:40The global obesity drug market reaches $97.8 billion by 2034 per Akviye
02:48Hanmi Pharmaceuticals HM17321, licensed to Genentech
02:53Targets fat loss and muscle preservation simultaneously via the UCN2 pathway
02:58A profile no approved drug achieves
03:01So, what does this mean for founders?
03:04Earlier, we said DigitalX's zero-fee launch is backed by $784 trillion won in distribution
03:11Here's what that actually means for you
03:13Mirai Asset is commoditizing transaction fees as an acquisition lever
03:17Compressing revenue assumptions for any fintech startup competing on spread or fee income
03:22Short pause
03:24On AI infrastructure, build Seoul area co-location lease terms with relocation optionality
03:30The regulatory floor is shifting
03:32The Korean Pharma BD pipeline for non-GLP-1 mechanisms is active
03:37Watch three things
03:39The Gwacheon vote on August 27th
03:41Its ordinance sets a precedent
03:44DigitalX's market share over 90 days
03:47Whether Mirai Asset's brokerage base converts to crypto volume
03:51Korean Pharma licensing in H2-2026
03:55Celtrian's CTG-32 pre-clinical data in November
03:59And Yuhan's non-GLP-1 lead compound selection by year-end
04:04That's today's AI Prism founders
04:07This episode was produced with AI assistance based on Seoul Economic Daily reporting
04:13and reviewed by a human editor
04:14AI Prism is a Juan Ifra award-winning series
04:18We'll be back tomorrow
04:20You've been listening to AI Prism from Seoul Economic Daily
04:25513-846-7605-Okay
댓글